DOI: 10.1128/mBio.02411-20
Article Information
PubMed
Published By
History
- Received August 29, 2020
- Accepted November 13, 2020
- Published online January 12, 2021.
Copyright & Usage
Copyright © 2021 Moustafa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Editors and / or Reviewers
- Robert A. Bonomo, Editor, Louis Stokes Veterans Affairs Medical Center
Author Information
- Dina A. Moustafaa,b,
- Ashley W. Wuc,
- Danniel Zamorac*,
- Seth M. Dalyc*,
- Carolyn R. Sturgec,
- Christine Pybusc,
- Bruce L. Gellerd,
- Joanna B. Goldberga,b,
- David E. Greenbergc,e
- aDepartment of Pediatrics, Division of Pulmonary, Allergy and Immunology, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA
- bEmory+Children’s Center for Cystic Fibrosis and Airway Disease Research, Emory University School of Medicine, Atlanta, Georgia, USA
- cDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- dDepartment of Microbiology, Oregon State University, Corvallis, Oregon, USA
- eDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Address correspondence to David E. Greenberg, david.greenberg{at}utsouthwestern.edu.
↵* Present address: Danniel Zamora, Department of Medicine, University of Washington, Seattle, Washington, USA; Seth M. Daly, Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
Citation Moustafa DA, Wu AW, Zamora D, Daly SM, Sturge CR, Pybus C, Geller BL, Goldberg JB, Greenberg DE. 2021. Peptide-conjugated phosphorodiamidate morpholino oligomers retain activity against multidrug-resistant Pseudomonas aeruginosa in vitro and in vivo. mBio 12:e02411-20. https://doi.org/10.1128/mBio.02411-20.
